Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eledon Pharmaceuticals (ELDN) EBITDA (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of EBITDA readings, the most recent being -$2.1 million for Q4 2017.

  • On a quarterly basis, EBITDA rose 43.73% to -$2.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$15.6 million, a 58.84% increase, with the full-year FY2025 number at -$45.6 million, down 26.08% from a year prior.
  • EBITDA hit -$2.1 million in Q4 2017 for Eledon Pharmaceuticals, up from -$3.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.1 million in Q4 2017 to a low of -$13.5 million in Q2 2016.
  • Median EBITDA over the past 5 years was -$6.3 million (2014), compared with a mean of -$7.3 million.
  • Biggest five-year swings in EBITDA: crashed 171.05% in 2015 and later surged 68.03% in 2017.
  • Eledon Pharmaceuticals' EBITDA stood at -$5.5 million in 2013, then dropped by 11.88% to -$6.2 million in 2014, then crashed by 78.48% to -$11.1 million in 2015, then skyrocketed by 66.24% to -$3.7 million in 2016, then surged by 43.73% to -$2.1 million in 2017.
  • The last three reported values for EBITDA were -$2.1 million (Q4 2017), -$3.0 million (Q3 2017), and -$6.7 million (Q2 2017) per Business Quant data.